We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00630630
Previous Study | Return to List | Next Study

Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00630630
Recruitment Status : Completed
First Posted : March 7, 2008
Last Update Posted : November 26, 2013
Information provided by:
UCB Pharma

Brief Summary:
The relationship between hormone cycling/fluctuations and the occurrence of seizures in women has received considerable discussion in the medical literature. This study investigated the efficacy and tolerability of LEV treatment for subjects with catamenial exacerbation of partial onset seizures.

Condition or disease Intervention/treatment Phase
Epilepsy Drug: Levetiracetam Other: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Adult Female Subjects (18 to 40 Years of Age) With C1 Catamenial Epilepsy
Study Start Date : November 2002
Actual Primary Completion Date : November 2003
Actual Study Completion Date : November 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy

Arm Intervention/treatment
Experimental: 1 Drug: Levetiracetam
Other Name: Keppra, ucbL059

Placebo Comparator: 2 Other: Placebo

Primary Outcome Measures :
  1. Percent change in catamenial seizure frequency.

Secondary Outcome Measures :
  1. Responder rate
  2. Number of days free from seizures per week
  3. Ratio of catamenial seizure frequency to non-catamenial seizure frequency
  4. Catamenial seizure frequency during each cycle
  5. Seizure frequency of catamenial and non-catamenial combined
  6. Non-catamenial seizure frequency
  7. Catamenial seizure frequency separately for ovulatory and anovulatory cycles
  8. Safety

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Non-pregnant and non-nursing females between the ages of 18 - 45 years of age;
  • out-patients with epilepsy experiencing uncontrolled simple and/or complex partial seizures with or without secondary generalization for a minimum of 2 years;
  • classifiable epilepsy according to the International Classification of Epileptic Seizures;
  • minimum of 2 seizures per 4 weeks during the Baseline Period, without exceeding 100 seizures per 4 weeks. The majority of seizures (>50%) must be partial onset, with or without secondary generalization;
  • exhibited, during the Baseline Period, a catamenial epilepsy type C1 pattern defined as at least a 70% increase of weekly seizure frequency during the menstrual phase compared to the luteal and follicular phases combined;
  • concurrent C2 catamenial epilepsy, defined as a 70% increase in daily seizure average during the ovulatory phase in comparison to the follicular and luteal phases combined, was permitted;
  • taking a minimum of one and a maximum of two antiepileptic drugs at a stable dose for a period of 4 weeks prior to the selection visit and during the duration of the trial;
  • vagal nerve stimulator (VNS) was permitted.

Exclusion Criteria:

  • using felbatol and presented clinically significant abnormalities with WBCs, RBCs, platelets, and/or hepatic function during felbatol treatment, and taking felbatol less than one year from the date of the Selection Visit;
  • partial onset seizures uncountable due to clustering during the last 3 months;
  • hormonal contraceptives that block menses within 6 months of the selection visit with no washout period permitted;
  • menstrual cycle length less than 21 days and greater than 35 days during the baseline evaluation;
  • alternative medications documented or purported to impact reproductive hormone levels, within the prior 2 months with no washout period permitted;
  • significantly irregular menstrual cycles or a history of frequent amenorrhea defined as two episodes within the preceding 6 months;
  • not taking hormonal contraceptives with more than one anovulatory cycle during the Baseline Period;
  • clinically significant medical condition requiring treatment, except for the study indication, which would prevent clear interpretation of the study results;
  • using the following classes of medications influencing the central nervous system: antipsychotics (typical and atypical), psychostimulants (except those containing methylphenidate, dextroamphetamine, or amphetamine used in the treatment of Attention Deficit Disorder), and hypnotics;
  • chronically dosing with benzodiazepines;
  • hospitalized for depression within 3 months prior to the selection visit.
  • history of attempting suicide within the last 3 years, or suicidal ideation within the last 3 months;
  • recent history (within the past two years) or presence of significant alcohol abuse or drug abuse;
  • clinical history of significantly impaired renal function with a estimate of creatinine clearance below 80 ml/min;
  • history of clinically significant cardiac conditions;
  • ALT/SGPT, AST/SGOT, alkaline phosphatase, or ?-GT value of more than 3 times the upper limit of the central laboratory reference value;
  • presence of a terminal illness;
  • presence of any clinically significant allergic condition to levetiracetam or pyrrolidone derivatives;
  • neutrophil count of less than 1800 per ?L.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00630630

Sponsors and Collaborators
UCB Pharma
Layout table for investigator information
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
Layout table for additonal information
Responsible Party: Study Director, UCB
ClinicalTrials.gov Identifier: NCT00630630    
Other Study ID Numbers: N01088
First Posted: March 7, 2008    Key Record Dates
Last Update Posted: November 26, 2013
Last Verified: September 2009
Keywords provided by UCB Pharma:
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Nootropic Agents